Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of E2730 in Healthy Subjects
NCT03451890Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2730 in epilepsy (8 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Mean maximum observed concentration at 288 hours, Time at which the highest drug concentration occurs at 288 hours and 12 more. Started Feb 2018; status: completed.
02
Drugs
E2730
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03451890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451890.